Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
NCT02604810
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
53
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immunodeficiency
Interventions
BIOLOGICAL:
IGIV-C 10%
BIOLOGICAL:
IGSC 20%
Sponsor
Grifols Therapeutics LLC